

Hypokalemic Paralysis: A Hidden Card of Several Autoimmune Diseases

Yelitza Velarde-Mejía¹, Rocío Gamboa-Cárdenas¹,
Manuel Ugarte-Gil^{1,2} and César Pastor Asurza^{1,3}

¹Rheumatology Department, Hospital Guillermo Almenara Irigoyen, La Victoria, Peru.

²School of Medicine, Universidad Científica del Sur, Villa El Salvador, Peru. ³School of Medicine, Universidad Nacional Mayor de San Marcos, Lima, Peru.

Clinical Medicine Insights: Arthritis and
Musculoskeletal Disorders
Volume 10: 1–4
© The Author(s) 2017
Reprints and permissions:
sagepub.co.uk/journalsPermissions.nav
DOI: 10.1177/1179544117722763



ABSTRACT: Acute hypokalemic paralysis is a rare and potentially fatal condition, with few related causes, one of which highlights distal renal tubular acidosis (dRTA). Distal renal tubular acidosis is a rare complication of several autoimmune diseases such as systemic lupus erythematosus, Sjögren's syndrome, and Hashimoto thyroiditis. We report a case of a lupic patient who presented rapidly progressive quadriparesis in the context of active renal disease. Research revealed severe refractory hypokalemia, metabolic acidosis, and alkaline urine suggestive of dRTA. We diagnosed Sjögren's syndrome based on sicca symptoms, an abnormal salivary glands' nuclear scan and the presence of anti-Ro/SSA and anti-La/SSB. In addition, the finding of thyroid peroxidase, thyroglobulin antibodies, and hypothyroidism led us to the diagnosis of Hashimoto thyroiditis. Due to the active renal involvement on the context of systemic lupus erythematosus and Sjögren's syndrome, the patient received immunosuppression with rituximab, resulting in a progressive and complete improvement.

KEYWORDS: lupus erythematosus, systemic, renal tubular acidosis, hypokalemias

RECEIVED: March 8, 2017. **ACCEPTED:** June 19, 2017.

PEER REVIEW: Four peer reviewers contributed to the peer review report. Reviewers' reports totaled 442 words, excluding any confidential comments to the academic editor.

TYPE: Case Report

FUNDING: The author(s) received no financial support for the research, authorship, and/or publication of this article.

DECLARATION OF CONFLICTING INTERESTS: The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

CORRESPONDING AUTHOR: Yelitza Velarde-Mejía, Rheumatology Department, Hospital Guillermo Almenara Irigoyen, Av. Grau s/n, La Victoria LIMA 13-15033, Peru. Email: ginger12887@hotmail.com

Introduction

Acute hypokalemic paralysis (AHP) is a potentially fatal but reversible condition which constitutes a challenge for emergency physicians. Secondary AHP is related to few conditions¹ and its ultimate course^{2,3} can be avoided with a rapid correction of hypokalemia. A proper clinical evaluation aimed at determining its underlying cause should always take place. One of its main causes, but many times overseen, is distal renal tubular acidosis (dRTA), which is a disorder characterized by an abnormal tubular acidification, resulting in hypokalemia and hyperchloremic metabolic acidosis with a normal serum anion gap (AG). Not frequently, dRTA could lead to AHP. Autoimmune disorders such as systemic lupus erythematosus (SLE), Sjögren's syndrome (SS), and Hashimoto thyroiditis (HT) may cause secondary dRTA^{4,5} and should always be excluded. We report the case of a patient with AHP secondary to dRTA, with more than one autoimmune disorder commonly associated with this condition, who had a good response to immunosuppression with rituximab (RTX).

Case Presentation

A 45-year-old woman was admitted to the emergency service with a 3-hour condition of tachypnea and flaccid quadriparesis. She had a 7-year history of SLE (her initial symptoms were malar rash, photosensitivity, nonerosive polyarthritis, and positive antinuclear antibodies with homogeneous pattern, titer 1/2560) whose main involvement was a proliferative glomerulonephritis and a recent diagnosis of hypothyroidism. Systemic lupus erythematosus was treated with prednisone (PDN) at

varying doses and hydroxychloroquine and mycophenolate mofetil (MMF) with doses between 1.5 and 3 g/d (current dosage) with complete renal response. Before 10 months of this episode, she presented a proteinuric flare (24-hour urine protein test: 760 mg/dL) poorly followed due to the lack of patient's compliance. Before 3 weeks of admission, she began complaining of mild myalgias and cramps which she attributed to her job. On admission, the patient denied vomiting, diarrhea, and the use of other drugs besides her usual medications. Her biologic functions were normal. She was tachypneic, tachycardic, with a normal blood pressure. Arterial blood gases demonstrated metabolic acidosis with normal serum AG, hypoxemia, and severe hypokalemia (K: 1.4 mEq/L) with electrocardiogram changes (presence of U wave and flattening of the T wave). Laboratory tests showed serum potassium at 1.7 mEq/L, high titers of anti-double-stranded DNA, and low complement. Cortisol, glucose, creatinine, calcium, magnesium, and liver profile were normal, and creatine kinase was mildly elevated (246 U/L). Urinalyses showed telescoped urinary sediment—an alkaline urinary pH (7.8). A renal ultrasonography revealed bilateral chronic nephropathy.

She received 2 intravenous replacement doses of potassium (5.4 mEq), but serum potassium remained low (1.7 mEq/L). She was admitted to the Rheumatology Department tachypneic with flaccid quadriparesis. Despite intense potassium replacement therapy, serum potassium remained in the hypokalemic range (<2.5 mEq/L) with persistent respiratory distress. Therefore, other possible causes of respiratory distress



such as pulmonary thromboembolism (normal lung scintigraphy), pulmonary hypertension, and pericardial effusion (determined by echocardiography) were ruled out. Clinical improvement was evident (normal respiratory rate and pattern and the ability to stand, walk, and sit up in bed unassisted) a few hours after a continuous potassium infusion pump was placed. Potassium replacement was continued with an oral solution of citric acid (Shohl's modified solution). In addition, the diagnosis of HT was confirmed on the context of high antithyroid peroxidase and antithyroglobulin antibody titers, and SS was diagnosed based on a 6-month history of sicca symptoms, a compatible salivary glands' nuclear scan, a positive rose bengal staining test, and positive anti-Ro/SSA and anti-La/SSB antibodies. Neither a kidney nor a salivary gland biopsy could be obtained due to patient's refusal. Finally, we confirmed the diagnosis of dRTA with alkaline urine (pH of 7.5) and positive urinary AG of +63 mEq/L (urine Na⁺ of 265 mEq/L, K⁺ of 38 mEq/L, and Cl⁻ of 240 mEq/L).

Active SLE with renal involvement despite optimal treatment with MMF was confirmed (SLEDAI [Systemic Lupus Erythematosus Disease Activity Index] 2K was 18), so we increased the PDN dose (0.5 mg/kg/d) and started RTX 1g biweekly. Patient was discharged with a strength of 4+/5 in proximal muscles of scapular grip, 5/5 in proximal muscles of pelvic grip, and with normal serum potassium levels (3.9 mEq/L). The patient has been followed up periodically; her muscle strength has remained normal, as well as her serum potassium levels. In addition, she has remained in clinical remission until the present (2 years after the event).

Discussion

The sudden onset of flaccid quadriparesis is an unusual but potentially lethal clinical condition seen in emergency departments. In our patient, the origin of her symptoms was severe hypokalemia, which led to paralysis and weakness of the respiratory muscles, which in turn contributed to hypoxemia. Acute hypokalemic paralysis is a relatively rare, potentially reversible cause of acute weakness; mortality occurs secondary to cardiac arrhythmias and respiratory failure.^{1,2} Therefore, it is of the utmost importance to consider it within the differential diagnosis in patients with this clinical condition. Hypokalemic paralysis can be primary or secondary, both lead to similar symptomatology. However, one of their main differences is the presence of an acid-base disorder in most of the patients with a secondary cause, plus the age of presentation in the primary form usually is under 25 years old and is predominant in men. Because the primary causes are finally determined by discarding, a meticulous analysis of all possible secondary causes is necessary. Fortunately, the causes of secondary AHP are limited (Table 1).³ Our patient was normotensive and denied vomiting, diarrhea, and the use of drugs other than her usual medications. Thyrotoxic paralysis, condition usually associated with iatrogenic thyrotoxicosis,⁴ was

Table 1. Common causes of hypokalemic paralysis.

a. Periodic paralysis due to intracellular shift
Thyrotoxic periodic paralysis
Hypertremic hypokalemia paralysis
b. Patients with hypokalemic paralysis due to potassium deficit
With hypochloremic metabolic alkalosis
Excessive vomiting
Diuretics
Bartter or Gitelman syndrome
Primary aldosteronism
With hyperchloremic metabolic acidosis
Distal renal tubular acidosis
Acute severe diarrhea

Modified with permission from Lin et al.³

also excluded because our patient had not modified her levothyroxine doses, and her thyroid-stimulating hormone (TSH) and triiodothyronine (T3) were normal (TSH: 0.82 mUI/L; T3: 4.0 pg/mL).

The diagnosis of dRTA was established on the basis of hyperchloremic metabolic acidosis with normal AG, alkaline urine, positive urinary AG (urine Na⁺ of 265 mEq/L, K⁺ of 38 mEq/L, and Cl⁻ of 240 mEq/L) and severe, refractory hypokalemia. In this disorder, the abnormal metabolic profile is a result of an excessive renal loss of potassium due to impaired secretion of H⁺ in the distal nephrons.⁵ It has distinctive features and could have a primary or secondary cause (Table 2).⁵⁻⁷ Acquired dRTA is often secondary to autoimmune diseases^{5,8} (SLE, SS, and HT, among them).

In HT, only a few cases of RTA have been reported. In murine models, thyroid hormones have been related to an abnormal expression of acid-base transporters, with increased membrane cell Na⁺/K⁺-ATPase pumps and reduced elimination of H⁺ ions in the distal nephron.¹⁰ The existence of antibodies against the collector tubules has been suggested as possible cause⁸ supporting the occasional need for corticosteroid treatment in these patients.¹¹ The prevalence of dRTA in SLE has not been asserted properly because of the few reported cases. Of note, concurrent active proliferative glomerulonephritis and RTA have been described.^{12,13} The precise mechanisms of tubular damage in SLE have not been elucidated yet; however, the deposition of immunoglobulins, complement, and plasma cells around tubules which may lead to irreversible damage suggests that the ongoing SLE autoimmune process is involved in its pathogenesis.¹⁴

In contrast to HT and SLE, tubulointerstitial renal involvement is a relative common manifestation of SS with an estimated prevalence of 5% to 10%.¹⁵⁻²⁰ The pathogenesis of dRTA in SS is not completely understood, but some studies suggest that the absence of H⁺-ATPase pump and the presence of autoantibodies to intercalated cells in the collector duct and against carbonic anhydrase in the distal nephron are the

Table 2. Conditions associated with distal RTA.

PRIMARY	SECONDARY
Autosomal-dominant RTA	Sjögren's syndrome
Autosomal-recessive RTA	Systemic lupus erythematosus
Pseudohypoaldosteronism type II	Chronic active hepatitis
	Hashimoto thyroiditis
	Takayasu arteritis
	Myeloma

Abbreviation: RTA, renal tubular acidosis.
Modified with permission from Laing et al.⁷

pathogenic mechanisms.^{21,22} Besides, there is a prominent interstitial infiltrate of lymphocytes and plasma cells,^{18,19,23} which invade the tubular membrane and lining epithelium, change the architecture, and generate a secretory defect in the distal tubules. Other facts that might support an autoimmune etiology in SS is a higher proportion of antinuclear, anti-Ro/SSA, and anti-La/SSB antibodies^{20,24} plus the correction of the urinary acidification after treatment with cyclophosphamide.²⁵ Distal renal tubular acidosis is generated due to tubulitis and/or tubular atrophy,²⁶ leading to the complete loss of H⁺-ATPase pumps in the collecting ducts. Their presence is valued as a more severe compromise²⁷ and is valued within the ESSDAI (EULAR Sjögren's syndrome disease activity index) score as low or moderate according to the presence of renal failure.²⁸ Early treatment with immunosuppressive drugs has been shown to maintain or improve renal function.²⁶

Although severe hypokalemia due to dRTA is rarely seen in autoimmune diseases,^{29–33} this condition can be life-threatening and could reflect the severity of the underlying autoimmune tubulointerstitial nephritis implicating the need for immunosuppressive treatment. Our patient presented tubular compromise associated with a refractory glomerular involvement and had a good response to RTX treatment. Of the tubulointerstitial nephritis cases reported in patients with SLE,^{34–37} to our knowledge, a favorable response to RTX has been reported in only one case.³⁸ In Sjögren's tubulointerstitial nephritis, there are few previous case reports in which RTX has been used.²⁶ Given the presence of tubulointerstitial involvement, the use of RTX can be supported on the basis of ectopic germinal centers and B-cell and T-cell aggregates, which have been strongly associated with the deposition of immune complexes in the renal tubules' basement membrane which are found in these patients.^{39–45}

In our patient, both SLE and SS could explain the tubulointerstitial compromise; however, in the presence of active glomerular involvement and because the severity of interstitial inflammation could predict progression to renal insufficiency,⁴⁶ our medical decision was to initiate RTX.

In conclusion, hypokalemia could be an inadvertent cause of flaccid paralysis and might even lead to death. Besides, refractory hypokalemia associated with metabolic acidosis should suggest the diagnosis of dRTA and lead to the search of secondary causes, being the autoimmune diseases (SLE, SS, and less frequently HT) the most important among them. Finally, potassium replacement and immunosuppressive treatment should be individually adjusted to each patient; long-term follow-up should monitor muscle strength, serum electrolytes, and renal function.

Acknowledgements

The authors thank Graciela S Alarcón, MD, MPH, MACR, for providing expert assistance in the review of this manuscript.

Author Contributions

All authors were responsible of case conception, critical revision and drafting of the manuscript. All authors approved the final version to be published.

REFERENCES

- Kalita J, Nair PP, Kumar G, Misra UK. Renal tubular acidosis presenting as respiratory paralysis: report of a case and review of literature. *Neurol India*. 2010;58:106–108.
- Kjeldsen K. Hypokalemia and sudden cardiac death. *Exp Clin Cardiol*. 2010;15:e96.
- Lin S-H, Chiu JS, Hsu CW, Chau T. A simple and rapid approach to hypokalemic paralysis. *Am J Emerg Med*. 2003;21:487–491.
- Falhammar H, Thorén M, Calissendorff J. Thyrotoxic periodic paralysis: clinical and molecular aspects. *Endocrine*. 2013;43:274–284.
- Soriano JR. Renal tubular acidosis: the clinical entity. *J Am Soc Nephrol*. 2002;13:2160–2170.
- Rose BD. *Clinical Physiology of Acid-Base and Electrolyte Disorders*. New York: McGraw-Hill; 2001.
- Laing CM, Unwin RJ. Renal tubular acidosis. *J Nephrol*. 2006;19:S46.
- Finn B, Young P, Bruetman JE, et al. Hypokalemia, acidosis tubular distal y tiroiditis de Hashimoto. *Nefrología*. 2008;28:569–570.
- Kayal AK, Goswami M, Das M, Jain R. Clinical and biochemical spectrum of hypokalemic paralysis in North: East India. *Ann Indian Acad Neurol*. 2013;16:211.
- Mohebbi N, Kovacicova J, Nowik M, Wagner CA. Thyroid hormone deficiency alters expression of acid-base transporters in rat kidney. *Am J Physiol Renal Physiol*. 2007;293:F416–F427.
- Suzuki N, Mitamura R, Ohmi H, et al. Hashimoto thyroiditis, distal renal tubular acidosis, pernicious anaemia and encephalopathy: a rare combination of auto-immune disorders in a 12-year-old girl. *Eur J Pediatr*. 1994;153:78–79.
- Ter Borg E, de Jong PE, Meijer SS, Kallenberg CG. Tubular dysfunction in proliferative lupus nephritis. *Am J Nephrol*. 1991;11:16–22.
- Li S, Liou LB, Fang JT, Tsai WP. Symptomatic renal tubular acidosis (RTA) in patients with systemic lupus erythematosus: an analysis of six cases with new association of type 4 RTA. *Rheumatology*. 2005;44:1176–1180.
- Pasternack A, Linder E. Renal tubular acidosis: an immunopathological study on four patients. *Clin Exp Immunol*. 1970;7:115.
- Muthukrishnan J, Galesić K, Vergles D. Sjogren's syndrome presenting as hypokalemic paralysis. *Med J Armed Forces India*. 2015;71:S172–S174.
- Basavaraj A, Badave RR, Kadam M, Kadam DB. Hypokalemic paralysis as a primary presentation of Fanconi's syndrome and distal renal tubular acidosis in a patient with primary Sjogren's syndrome. *Neurol India*. 2015;63:446.
- Toosi TD, Naderi N, Movassaghi S, Seradj MH, Khalvat A, Shahbazi F. Secondary Sjogren's syndrome presenting with hypokalemic periodic paralysis. *Oxf Med Case Reports*. 2014;2014:135–137.
- Winer RL, Cohen AH, Sawhney AS, Gorman JT. Sjogren's syndrome with immune-complex tubulointerstitial renal disease. *Clin Immunol Immunopathol*. 1977;8:494–503.
- Eneström S, Denneberg T, Eriksson P. Histopathology of renal biopsies with correlation to clinical findings in primary Sjogren's syndrome. *Clin Exp Rheumatol*. 1994;13:697–703.

20. Aasarød K, Haga HJ, Berg KJ, Hammerstrøm J, Jørstad S. Renal involvement in primary Sjögren's syndrome. *QJM*. 2000;93:297–304.
21. Pertovaara M, Bootorabi F, Kuuslahti M, Pasternack A, Parkkila S. Novel carbonic anhydrase autoantibodies and renal manifestations in patients with primary Sjögren's syndrome. *Rheumatology*. 2011;50:1453–1457.
22. Joo K, Jeon US, Han JS, et al. Absence of H (+)-ATPase in the intercalated cells of renal tissues in classic distal renal tubular acidosis. *Clin Nephrol*. 1998;49:226–231.
23. Talal N, Zisman E, Schur PH. Renal tubular acidosis, glomerulonephritis and immunologic factors in Sjogren's syndrome. *Arthritis Rheum*. 1968;11:774–786.
24. Pertovaara M, Korpela M, Kouri T, Pasternack A. The occurrence of renal involvement in primary Sjögren's syndrome: a study of 78 patients. *Rheumatology*. 1999;38:1113–1120.
25. Zawadzki J. Permeability defect with bicarbonate leak as a mechanism of immune-related distal renal tubular acidosis. *Am J Kidney Dis*. 1998;31:527–532.
26. Maripuri S, Grande JP, Osborn TG, et al. Renal involvement in primary Sjögren's syndrome: a clinicopathologic study. *Clin J Am Soc Nephrol*. 2009;4:1423–1431.
27. Agarwal A, Kumar P, Gupta N. Pediatric Sjogren syndrome with distal renal tubular acidosis and autoimmune hypothyroidism: an uncommon association. *CEN Case Rep*. 2015;4:200–205.
28. Seror R, Theander E, Brun JG, et al. Validation of EULAR primary Sjogren's syndrome disease activity (ESSDAI) and patient indexes (ESSPRI). *Ann Rheum Dis*. 2015;74:859–866.
29. Gera C, Mohapatra D, Calton N. Hypokalaemic paralysis secondary to distal renal tubular acidosis as the presenting symptom of systemic lupus erythematosus. *Singapore Med J*. 2011;52:e1–e3.
30. Koul P, Wahid A. Distal renal tubular acidosis and hypokalemic paralysis in a patient with hypothyroidism. *Saudi J Kidney Dis Transpl*. 2011;22:1014.
31. Koul P, Wahid A, Shah B. Systemic lupus erythematosus with distal renal tubular acidosis presenting as hypokalemic paralysis with respiratory failure. *Saudi J Kidney Dis Transpl*. 2003;14:190.
32. Ray S, Pillai MGK, Kurian G, Unni VN. Latent systemic lupus erythematosus presenting as hypokalemic paralysis. *Indian J Nephrol*. 2005;15:98.
33. Chou CL, Cheng C-J, Wu Y-Y, Lin S-H. An unusual manifestation of systemic lupus erythematosus: hypokalaemic paralysis. *Int J Clin Pract*. 2008;62:969–972.
34. Mori Y, Kishimoto N, Yamahara H, et al. Predominant tubulointerstitial nephritis in a patient with systemic lupus nephritis. *Clin Exp Nephrol*. 2005;9:79–84.
35. Singh AK, Ucci A, Madias NE. Predominant tubulointerstitial lupus nephritis. *Am J Kidney Dis*. 1996;27:273–278.
36. Ali A, Al-Windawi S. Tubulointerstitial lupus nephritis. *J Nephropathol*. 2013;2:75.
37. O'Dell JR, Hays RC, Guggenheim SJ, Steigerwald JC. Tubulointerstitial renal disease in systemic lupus erythematosus. *Arch Intern Med*. 1985;145:1996–1999.
38. Melander C, Sallée M, Trolliet P, et al. Rituximab in severe lupus nephritis: early B-cell depletion affects long-term renal outcome. *Clin J Am Soc Nephrol*. 2009;4:579–587.
39. Chang A, Henderson SG, Brandt D, et al. In situ B cell-mediated immune responses and tubulointerstitial inflammation in human lupus nephritis. *J Immunol*. 2011;186:1849–1860.
40. Bogdanović R, Basta-Jovanović G, Putnik J, et al. Renal involvement in primary Sjogren syndrome of childhood: case report and literature review. *Mod Rheumatol*. 2013;23:182–189.
41. Kidder D, Rutherford E, Kipgen D, Fleming S, Geddes C, Stewart GA. Kidney biopsy findings in primary Sjogren syndrome. *Nephrol Dial Transplant*. 2015;30:1363–1369.
42. Pijpe J, Vissink A, Van der Wal JE, Kallenberg CG. Interstitial nephritis with infiltration of IgG-kappa positive plasma cells in a patient with Sjögren's syndrome. *Rheumatology*. 2004;43:108–110.
43. Bossini N, Savoldi S, Franceschini F, et al. Clinical and morphological features of kidney involvement in primary Sjögren's syndrome. *Nephrol Dial Transplant*. 2001;16:2328–2336.
44. Takaya M, Ichikawa Y, Shimizu H, et al. T lymphocyte subsets of the infiltrating cells in the salivary gland and kidney of a patient with Sjogren's syndrome associated with interstitial nephritis. *Clin Exp Rheumatol*. 1984;3:259–263.
45. Hayakawa S, Nakabayashi K, Karube M, et al. Tubulointerstitial immune complex nephritis in a patient with systemic lupus erythematosus: role of peritubular capillaritis with immune complex deposits in the pathogenesis of the tubulointerstitial nephritis. *Clin Exp Nephrol*. 2006;10:146–151.
46. Hill GS, Delahousse M, Nochy D, et al. Outcome of relapse in lupus nephritis: roles of reversal of renal fibrosis and response of inflammation to therapy. *Kidney Int*. 2002;61:2176–2186.